About Us | Contact

Dr. Mark Lamet Investigator

Gastroenterology Memorial Regional Hospital NPI1972554731
Update NPI

Open Payments

Note

The following payment details are based on a national transparency program known as the Sunshine Act that collects and publishes information about financial relationships between the health care industry (i.e. drug and device manufactures) and providers. These relationships may involve payment to providers for things such as research, speaking engagment, travel, gifts etc. Not all of these payment involve monetary compensations and may include batering of drugs or devices.

Total Payment Worth

$118,629.35
from 363 payments in the last 6 years

Total Cash or Cash Equivalent

$108,087.06
from 110 payments in the last 6 years

Total In-kind Items & Services

$10,542.29
from 253 payments in the last 6 years

Nature of Payments

Last 6 Years
Chart will render here...

Yearly Breakdown

Chart will render here...

Payment Details

Date Payment Type Form of Payment Item/Service Payment Amount
01/25/2021 General (Non-Research) In-kind items and services Food and Beverage $12.40 Details
Payment from Salix Pharmaceuticals, a division of Bausch Health US, LLC
Payment Record ID 850420911
02/01/2021 General (Non-Research) In-kind items and services Food and Beverage $13.00 Details
Payment from Salix Pharmaceuticals, a division of Bausch Health US, LLC
Payment Record ID 850418853
02/01/2021 General (Non-Research) In-kind items and services Food and Beverage $16.08 Details
Payment from Salix Pharmaceuticals, a division of Bausch Health US, LLC
Payment Record ID 850400955
12/16/2021 General (Non-Research) In-kind items and services Food and Beverage $3.09 Details
Payment from Salix Pharmaceuticals, a division of Bausch Health US, LLC
Payment Record ID 850391333
09/15/2021 General (Non-Research) In-kind items and services Food and Beverage $15.79 Details
Payment from Salix Pharmaceuticals, a division of Bausch Health US, LLC
Payment Record ID 850375307
10/12/2021 General (Non-Research) In-kind items and services Food and Beverage $18.45 Details
Payment from Salix Pharmaceuticals, a division of Bausch Health US, LLC
Payment Record ID 850364257
04/19/2021 General (Non-Research) In-kind items and services Food and Beverage $17.05 Details
Payment from Salix Pharmaceuticals, a division of Bausch Health US, LLC
Payment Record ID 850339491
10/28/2021 General (Non-Research) In-kind items and services Food and Beverage $104.17 Details
Payment from Salix Pharmaceuticals, a division of Bausch Health US, LLC
Payment Record ID 850314393
12/16/2021 General (Non-Research) In-kind items and services Food and Beverage $11.21 Details
Payment from Salix Pharmaceuticals, a division of Bausch Health US, LLC
Payment Record ID 850273613
09/08/2021 General (Non-Research) In-kind items and services Food and Beverage $10.61 Details
Payment from Salix Pharmaceuticals, a division of Bausch Health US, LLC
Payment Record ID 850265657
12/16/2021 General (Non-Research) In-kind items and services Food and Beverage $14.61 Details
Payment from Salix Pharmaceuticals, a division of Bausch Health US, LLC
Payment Record ID 850233279
04/12/2021 General (Non-Research) In-kind items and services Food and Beverage $8.75 Details
Payment from Salix Pharmaceuticals, a division of Bausch Health US, LLC
Payment Record ID 850201097
09/08/2021 General (Non-Research) In-kind items and services Food and Beverage $5.52 Details
Payment from Salix Pharmaceuticals, a division of Bausch Health US, LLC
Payment Record ID 850095341
04/26/2021 General (Non-Research) In-kind items and services Food and Beverage $24.60 Details
Payment from Gilead Sciences, Inc.
Payment Record ID 848225895
02/23/2021 General (Non-Research) In-kind items and services Food and Beverage $20.82 Details
Payment from Gilead Sciences, Inc.
Payment Record ID 848225893
01/20/2021 General (Non-Research) In-kind items and services Food and Beverage $26.49 Details
Payment from Gilead Sciences, Inc.
Payment Record ID 848225891
10/21/2021 General (Non-Research) In-kind items and services Food and Beverage $20.51 Details
Payment from Daiichi Sankyo Inc.
Payment Record ID 836329521
06/24/2021 General (Non-Research) In-kind items and services Food and Beverage $15.64 Details
Payment from Daiichi Sankyo Inc.
Payment Record ID 836299879
02/04/2021 General (Non-Research) In-kind items and services Food and Beverage $15.93 Details
Payment from Daiichi Sankyo Inc.
Payment Record ID 836257053
11/29/2021 General (Non-Research) In-kind items and services Food and Beverage $20.86 Details
Payment from Nestle HealthCare Nutrition Inc.
Payment Record ID 820919031
04/20/2021 General (Non-Research) In-kind items and services Food and Beverage $17.27 Details
Payment from Nestle HealthCare Nutrition Inc.
Payment Record ID 820919027
03/23/2021 General (Non-Research) In-kind items and services Food and Beverage $15.37 Details
Payment from Nestle HealthCare Nutrition Inc.
Payment Record ID 820919023
06/24/2021 General (Non-Research) In-kind items and services Food and Beverage $24.56 Details
Payment from Braintree Laboratories, Inc.
Payment Record ID 805251165
10/20/2021 General (Non-Research) In-kind items and services Food and Beverage $14.48 Details
Payment from RedHill Biopharma Inc.
Payment Record ID 799929437
09/13/2021 General (Non-Research) In-kind items and services Food and Beverage $17.26 Details
Payment from RedHill Biopharma Inc.
Payment Record ID 799929435
08/26/2021 General (Non-Research) In-kind items and services Food and Beverage $17.93 Details
Payment from RedHill Biopharma Inc.
Payment Record ID 799929433
10/28/2021 General (Non-Research) In-kind items and services Food and Beverage $13.46 Details
Payment from AbbVie Inc.
Payment Record ID 795213713
10/05/2021 General (Non-Research) In-kind items and services Food and Beverage $28.87 Details
Payment from AbbVie Inc.
Payment Record ID 795213707
05/17/2021 General (Non-Research) In-kind items and services Food and Beverage $14.58 Details
Payment from AbbVie Inc.
Payment Record ID 795213704
11/03/2021 General (Non-Research) Cash or cash equivalent Food and Beverage $17.41 Details
Payment from BOSTON SCIENTIFIC CORPORATION
Payment Record ID 793768999
12/01/2021 General (Non-Research) In-kind items and services Education $99.95 Details
Payment from Janssen Biotech, Inc.
Payment Record ID 788877947
11/16/2021 General (Non-Research) In-kind items and services Food and Beverage $17.57 Details
Payment from Janssen Biotech, Inc.
Payment Record ID 788877945
11/16/2021 General (Non-Research) In-kind items and services Food and Beverage $0.20 Details
Payment from Janssen Biotech, Inc.
Payment Record ID 788877943
11/16/2021 General (Non-Research) In-kind items and services Food and Beverage $2.45 Details
Payment from Janssen Biotech, Inc.
Payment Record ID 788877941
10/20/2021 General (Non-Research) In-kind items and services Food and Beverage $14.80 Details
Payment from Janssen Biotech, Inc.
Payment Record ID 788877939
10/19/2021 General (Non-Research) In-kind items and services Food and Beverage $1.67 Details
Payment from Janssen Biotech, Inc.
Payment Record ID 788877937
09/14/2021 General (Non-Research) In-kind items and services Food and Beverage $2.39 Details
Payment from Janssen Biotech, Inc.
Payment Record ID 788877935
09/16/2021 General (Non-Research) In-kind items and services Food and Beverage $17.32 Details
Payment from Janssen Biotech, Inc.
Payment Record ID 788877933
07/28/2021 General (Non-Research) In-kind items and services Food and Beverage $14.81 Details
Payment from Janssen Biotech, Inc.
Payment Record ID 788877931
07/28/2021 General (Non-Research) In-kind items and services Food and Beverage $1.26 Details
Payment from Janssen Biotech, Inc.
Payment Record ID 788877929
08/25/2021 General (Non-Research) Cash or cash equivalent Food and Beverage $16.67 Details
Payment from Celgene Corporation
Payment Record ID 783679249
09/24/2020 General (Non-Research) In-kind items and services Food and Beverage $18.73 Details
Payment from Braintree Laboratories, Inc.
Payment Record ID 750547611
10/15/2020 General (Non-Research) Cash or cash equivalent Food and Beverage $14.21 Details
Payment from IRONWOOD PHARMACEUTICALS, INC
Payment Record ID 749777317
08/06/2020 General (Non-Research) In-kind items and services Food and Beverage $15.59 Details
Payment from Gilead Sciences, Inc.
Payment Record ID 747981877
11/05/2020 General (Non-Research) In-kind items and services Food and Beverage $16.28 Details
Payment from Daiichi Sankyo Inc.
Payment Record ID 739504725
09/15/2020 General (Non-Research) In-kind items and services Food and Beverage $18.71 Details
Payment from Daiichi Sankyo Inc.
Payment Record ID 739499101
12/21/2020 General (Non-Research) In-kind items and services Food and Beverage $16.31 Details
Payment from Salix Pharmaceuticals, a division of Bausch Health US, LLC
Payment Record ID 737560603
12/07/2020 General (Non-Research) In-kind items and services Food and Beverage $15.99 Details
Payment from Salix Pharmaceuticals, a division of Bausch Health US, LLC
Payment Record ID 737560601
02/20/2020 General (Non-Research) In-kind items and services Food and Beverage $16.74 Details
Payment from Salix Pharmaceuticals, a division of Bausch Health US, LLC
Payment Record ID 737560599
01/29/2020 General (Non-Research) In-kind items and services Food and Beverage $13.23 Details
Payment from Salix Pharmaceuticals, a division of Bausch Health US, LLC
Payment Record ID 737560597
01/17/2020 Research Cash or cash equivalent $982.20 Details
Payment from Celgene Corporation
Paymment Research Study RPC01-3201
Payment Record ID 736445581
11/04/2020 General (Non-Research) In-kind items and services Food and Beverage $20.16 Details
Payment from RedHill Biopharma Inc.
Payment Record ID 730058849
07/15/2020 General (Non-Research) In-kind items and services Food and Beverage $17.59 Details
Payment from RedHill Biopharma Inc.
Payment Record ID 730052429
03/04/2020 General (Non-Research) In-kind items and services Food and Beverage $30.81 Details
Payment from RedHill Biopharma Inc.
Payment Record ID 730045131
01/28/2020 Research In-kind items and services $1176.64 Details
Payment from Eli Lilly and Company
Paymment Research Study A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL, PLACEBO-CONTROLLED INDUCTION STUDY OF MIRIKIZUMAB IN CONVENTIONAL-FAILED AND BIOLOGIC-FAILED PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (LUCENT 1)
Clinical Trials Gov ID NCT03518086
Payment Record ID 728722066
10/13/2020 General (Non-Research) In-kind items and services Food and Beverage $22.47 Details
Payment from AbbVie Inc.
Payment Record ID 721971497
06/22/2020 General (Non-Research) In-kind items and services Food and Beverage $18.00 Details
Payment from AbbVie Inc.
Payment Record ID 721971491
09/17/2020 Research Cash or cash equivalent $1900.00 Details
Payment from AbbVie Inc.
Payment Record ID 721142639
03/13/2019 General (Non-Research) In-kind items and services Food and Beverage $14.83 Details
Payment from Ironwood Pharmaceuticals, Inc
Payment Record ID 709210791
03/12/2019 General (Non-Research) In-kind items and services Food and Beverage $12.39 Details
Payment from Ironwood Pharmaceuticals, Inc
Payment Record ID 709210789
12/13/2019 General (Non-Research) In-kind items and services Education $9.41 Details
Payment from Braintree Laboratories, Inc.
Payment Record ID 703860637
11/01/2019 General (Non-Research) In-kind items and services Food and Beverage $16.63 Details
Payment from Braintree Laboratories, Inc.
Payment Record ID 703860635
11/01/2019 General (Non-Research) In-kind items and services Education $9.41 Details
Payment from Braintree Laboratories, Inc.
Payment Record ID 703860633
10/15/2019 General (Non-Research) In-kind items and services Education $9.41 Details
Payment from Braintree Laboratories, Inc.
Payment Record ID 703860631
08/15/2019 General (Non-Research) In-kind items and services Education $6.96 Details
Payment from Braintree Laboratories, Inc.
Payment Record ID 703860629
07/03/2019 General (Non-Research) In-kind items and services Education $6.96 Details
Payment from Braintree Laboratories, Inc.
Payment Record ID 703860627
06/27/2019 General (Non-Research) In-kind items and services Education $6.96 Details
Payment from Braintree Laboratories, Inc.
Payment Record ID 703860625
05/28/2019 General (Non-Research) In-kind items and services Food and Beverage $22.88 Details
Payment from Braintree Laboratories, Inc.
Payment Record ID 703860623
05/28/2019 General (Non-Research) In-kind items and services Education $6.96 Details
Payment from Braintree Laboratories, Inc.
Payment Record ID 703860621
05/21/2019 General (Non-Research) In-kind items and services Education $9.41 Details
Payment from Braintree Laboratories, Inc.
Payment Record ID 703860619
04/18/2019 General (Non-Research) In-kind items and services Education $9.41 Details
Payment from Braintree Laboratories, Inc.
Payment Record ID 703860617
03/29/2019 General (Non-Research) In-kind items and services Education $9.41 Details
Payment from Braintree Laboratories, Inc.
Payment Record ID 703860615
03/22/2019 General (Non-Research) In-kind items and services Education $6.38 Details
Payment from Braintree Laboratories, Inc.
Payment Record ID 703860613
03/22/2019 General (Non-Research) In-kind items and services Education $9.41 Details
Payment from Braintree Laboratories, Inc.
Payment Record ID 703860611
03/07/2019 General (Non-Research) In-kind items and services Food and Beverage $20.00 Details
Payment from Braintree Laboratories, Inc.
Payment Record ID 703860609
03/01/2019 General (Non-Research) In-kind items and services Education $9.41 Details
Payment from Braintree Laboratories, Inc.
Payment Record ID 703860607
01/18/2019 General (Non-Research) In-kind items and services Food and Beverage $17.79 Details
Payment from Braintree Laboratories, Inc.
Payment Record ID 703860605
01/18/2019 General (Non-Research) In-kind items and services Education $9.41 Details
Payment from Braintree Laboratories, Inc.
Payment Record ID 703860603
01/15/2019 General (Non-Research) In-kind items and services Education $1.68 Details
Payment from Braintree Laboratories, Inc.
Payment Record ID 703860601
01/15/2019 General (Non-Research) In-kind items and services Education $9.41 Details
Payment from Braintree Laboratories, Inc.
Payment Record ID 703860599
01/29/2019 General (Non-Research) In-kind items and services Food and Beverage $19.17 Details
Payment from Intercept Pharmaceuticals, Inc.
Payment Record ID 702088845
12/16/2019 General (Non-Research) In-kind items and services Food and Beverage $20.72 Details
Payment from Salix Pharmaceuticals, a division of Bausch Health US, LLC
Payment Record ID 684794973
12/05/2019 General (Non-Research) In-kind items and services Food and Beverage $3.13 Details
Payment from Salix Pharmaceuticals, a division of Bausch Health US, LLC
Payment Record ID 684794970
12/05/2019 General (Non-Research) In-kind items and services Food and Beverage $18.59 Details
Payment from Salix Pharmaceuticals, a division of Bausch Health US, LLC
Payment Record ID 684794967
11/26/2019 General (Non-Research) In-kind items and services Food and Beverage $3.13 Details
Payment from Salix Pharmaceuticals, a division of Bausch Health US, LLC
Payment Record ID 684794963
11/26/2019 General (Non-Research) In-kind items and services Food and Beverage $11.65 Details
Payment from Salix Pharmaceuticals, a division of Bausch Health US, LLC
Payment Record ID 684794961
11/12/2019 General (Non-Research) In-kind items and services Food and Beverage $17.13 Details
Payment from Salix Pharmaceuticals, a division of Bausch Health US, LLC
Payment Record ID 684794957
11/12/2019 General (Non-Research) In-kind items and services Food and Beverage $4.14 Details
Payment from Salix Pharmaceuticals, a division of Bausch Health US, LLC
Payment Record ID 684794955
09/30/2019 General (Non-Research) In-kind items and services Food and Beverage $13.54 Details
Payment from Salix Pharmaceuticals, a division of Bausch Health US, LLC
Payment Record ID 684794951
08/27/2019 General (Non-Research) In-kind items and services Food and Beverage $10.82 Details
Payment from Salix Pharmaceuticals, a division of Bausch Health US, LLC
Payment Record ID 684794949
08/27/2019 General (Non-Research) In-kind items and services Food and Beverage $12.59 Details
Payment from Salix Pharmaceuticals, a division of Bausch Health US, LLC
Payment Record ID 684794945
08/16/2019 General (Non-Research) In-kind items and services Food and Beverage $17.56 Details
Payment from Salix Pharmaceuticals, a division of Bausch Health US, LLC
Payment Record ID 684794942
04/08/2019 General (Non-Research) In-kind items and services Food and Beverage $3.79 Details
Payment from Salix Pharmaceuticals, a division of Bausch Health US, LLC
Payment Record ID 684794939
04/08/2019 General (Non-Research) In-kind items and services Food and Beverage $17.16 Details
Payment from Salix Pharmaceuticals, a division of Bausch Health US, LLC
Payment Record ID 684794935
03/26/2019 General (Non-Research) In-kind items and services Food and Beverage $15.55 Details
Payment from Salix Pharmaceuticals, a division of Bausch Health US, LLC
Payment Record ID 684794933
01/22/2019 General (Non-Research) In-kind items and services Food and Beverage $15.48 Details
Payment from Salix Pharmaceuticals, a division of Bausch Health US, LLC
Payment Record ID 684794929
01/22/2019 General (Non-Research) In-kind items and services Food and Beverage $21.10 Details
Payment from Salix Pharmaceuticals, a division of Bausch Health US, LLC
Payment Record ID 684794927
01/07/2019 General (Non-Research) In-kind items and services Food and Beverage $11.01 Details
Payment from Takeda Pharmaceuticals U.S.A., Inc.
Payment Record ID 682075203
11/27/2019 General (Non-Research) In-kind items and services Food and Beverage $19.20 Details
Payment from Gilead Sciences, Inc.
Payment Record ID 681548095
09/24/2019 General (Non-Research) In-kind items and services Food and Beverage $23.02 Details
Payment from Gilead Sciences, Inc.
Payment Record ID 681548093
09/24/2019 General (Non-Research) In-kind items and services Food and Beverage $9.73 Details
Payment from Gilead Sciences, Inc.
Payment Record ID 681548091
07/22/2019 General (Non-Research) In-kind items and services Food and Beverage $20.51 Details
Payment from Gilead Sciences, Inc.
Payment Record ID 681548089
07/17/2019 General (Non-Research) In-kind items and services Food and Beverage $16.03 Details
Payment from Gilead Sciences, Inc.
Payment Record ID 681548087
07/17/2019 General (Non-Research) In-kind items and services Food and Beverage $11.36 Details
Payment from Gilead Sciences, Inc.
Payment Record ID 681548085
05/20/2019 General (Non-Research) In-kind items and services Food and Beverage $3.67 Details
Payment from Gilead Sciences, Inc.
Payment Record ID 681548083
05/15/2019 General (Non-Research) In-kind items and services Food and Beverage $11.19 Details
Payment from Gilead Sciences, Inc.
Payment Record ID 681548081
05/15/2019 General (Non-Research) In-kind items and services Food and Beverage $9.90 Details
Payment from Gilead Sciences, Inc.
Payment Record ID 681548079
03/18/2019 General (Non-Research) In-kind items and services Food and Beverage $13.01 Details
Payment from Gilead Sciences, Inc.
Payment Record ID 681548077
03/18/2019 General (Non-Research) In-kind items and services Food and Beverage $10.62 Details
Payment from Gilead Sciences, Inc.
Payment Record ID 681548075
03/11/2019 General (Non-Research) In-kind items and services Food and Beverage $16.84 Details
Payment from Gilead Sciences, Inc.
Payment Record ID 681548073
03/11/2019 General (Non-Research) In-kind items and services Food and Beverage $11.34 Details
Payment from Gilead Sciences, Inc.
Payment Record ID 681548071
07/17/2019 Research Cash or cash equivalent Drug $8970.19 Details
Payment from Celgene Corporation
Paymment Research Study RPC01-3204
Payment Record ID 675414253
01/16/2019 Research Cash or cash equivalent Drug $25470.99 Details
Payment from Celgene Corporation
Paymment Research Study RPC01-3201
Payment Record ID 675414251
11/15/2019 General (Non-Research) In-kind items and services Food and Beverage $11.76 Details
Payment from Allergan Inc.
Payment Record ID 670696917
09/06/2019 General (Non-Research) In-kind items and services Food and Beverage $12.50 Details
Payment from Allergan Inc.
Payment Record ID 670696913
09/05/2019 General (Non-Research) In-kind items and services Food and Beverage $15.15 Details
Payment from Allergan Inc.
Payment Record ID 670696909
08/12/2019 General (Non-Research) In-kind items and services Food and Beverage $11.01 Details
Payment from Allergan Inc.
Payment Record ID 670696907
07/29/2019 General (Non-Research) In-kind items and services Food and Beverage $14.67 Details
Payment from Allergan Inc.
Payment Record ID 670696903
04/08/2019 General (Non-Research) In-kind items and services Food and Beverage $14.75 Details
Payment from Janssen Biotech, Inc.
Payment Record ID 658544419
04/08/2019 General (Non-Research) In-kind items and services Food and Beverage $19.35 Details
Payment from Janssen Biotech, Inc.
Payment Record ID 658544413
04/04/2019 General (Non-Research) In-kind items and services Food and Beverage $26.16 Details
Payment from Ferring Pharmaceuticals Inc.
Payment Record ID 655199875
12/19/2019 Research In-kind items and services $522.53 Details
Payment from Eli Lilly and Company
Paymment Research Study A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-ARM, PLACEBO-CONTROLLED MAINTENANCE STUDY OF MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (LUCENT 2)
Clinical Trials Gov ID NCT03524092
Payment Record ID 654283497
06/25/2019 Research In-kind items and services $941.95 Details
Payment from Eli Lilly and Company
Paymment Research Study A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL, PLACEBO-CONTROLLED INDUCTION STUDY OF MIRIKIZUMAB IN CONVENTIONAL-FAILED AND BIOLOGIC-FAILED PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (LUCENT 1)
Clinical Trials Gov ID NCT03518086
Payment Record ID 654282681
10/28/2019 General (Non-Research) In-kind items and services Food and Beverage $23.06 Details
Payment from Apollo Endosurgery US Inc
Payment Record ID 650088729
01/14/2019 General (Non-Research) In-kind items and services Food and Beverage $27.70 Details
Payment from Apollo Endosurgery US Inc
Payment Record ID 650087157
10/11/2018 General (Non-Research) In-kind items and services Food and Beverage $13.14 Details
Payment from Synergy Pharmaceuticals Inc
Payment Record ID 617272337
10/11/2018 General (Non-Research) In-kind items and services Food and Beverage $19.10 Details
Payment from Synergy Pharmaceuticals Inc
Payment Record ID 617272333
05/09/2018 General (Non-Research) In-kind items and services Food and Beverage $17.65 Details
Payment from Synergy Pharmaceuticals Inc
Payment Record ID 617227609
11/16/2018 General (Non-Research) Cash or cash equivalent Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $200.00 Details
Payment from ReShape Lifesciences Inc.
Payment Record ID 616335759
11/27/2018 General (Non-Research) Cash or cash equivalent Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $150.00 Details
Payment from ReShape Lifesciences Inc.
Payment Record ID 616171597
11/16/2018 General (Non-Research) Cash or cash equivalent Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $200.00 Details
Payment from ReShape Lifesciences Inc.
Payment Record ID 616171519
07/25/2018 General (Non-Research) In-kind items and services Food and Beverage $19.84 Details
Payment from Intercept Pharmaceuticals, Inc.
Payment Record ID 615234149
05/07/2018 General (Non-Research) In-kind items and services Food and Beverage $22.42 Details
Payment from Intercept Pharmaceuticals, Inc.
Payment Record ID 615234147
07/23/2018 General (Non-Research) In-kind items and services Food and Beverage $18.79 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 604542857
02/13/2018 General (Non-Research) In-kind items and services Food and Beverage $14.24 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 604239257
12/05/2018 Research Cash or cash equivalent Drug $4000.00 Details
Payment from Celgene Corporation
Paymment Research Study RPC01-3201
Payment Record ID 595025213
11/26/2018 General (Non-Research) In-kind items and services Food and Beverage $11.71 Details
Payment from Allergan Inc.
Payment Record ID 594540130
10/30/2018 General (Non-Research) In-kind items and services Food and Beverage $11.31 Details
Payment from Allergan Inc.
Payment Record ID 594540107
08/22/2018 General (Non-Research) In-kind items and services Food and Beverage $15.11 Details
Payment from Allergan Inc.
Payment Record ID 594540098
05/16/2018 General (Non-Research) In-kind items and services Food and Beverage $13.17 Details
Payment from Allergan Inc.
Payment Record ID 594540074
01/26/2018 General (Non-Research) In-kind items and services Food and Beverage $12.73 Details
Payment from Allergan Inc.
Payment Record ID 594540065
10/08/2018 General (Non-Research) In-kind items and services Food and Beverage $10.62 Details
Payment from Gilead Sciences, Inc.
Payment Record ID 592471403
08/28/2018 General (Non-Research) In-kind items and services Food and Beverage $10.86 Details
Payment from Gilead Sciences, Inc.
Payment Record ID 592471399
06/11/2018 General (Non-Research) In-kind items and services Food and Beverage $22.62 Details
Payment from Gilead Sciences, Inc.
Payment Record ID 592471396
04/09/2018 General (Non-Research) In-kind items and services Food and Beverage $13.52 Details
Payment from Gilead Sciences, Inc.
Payment Record ID 592471391
09/05/2018 General (Non-Research) In-kind items and services Food and Beverage $13.06 Details
Payment from Takeda Pharmaceuticals U.S.A., Inc.
Payment Record ID 589969187
12/19/2018 General (Non-Research) In-kind items and services Food and Beverage $21.77 Details
Payment from Salix Pharmaceuticals, a division of Bausch Health US, LLC
Payment Record ID 589415961
12/19/2018 General (Non-Research) In-kind items and services Food and Beverage $16.93 Details
Payment from Salix Pharmaceuticals, a division of Bausch Health US, LLC
Payment Record ID 589415957
12/11/2018 General (Non-Research) In-kind items and services Food and Beverage $53.42 Details
Payment from Salix Pharmaceuticals, a division of Bausch Health US, LLC
Payment Record ID 589415952
11/20/2018 General (Non-Research) In-kind items and services Food and Beverage $20.93 Details
Payment from Salix Pharmaceuticals, a division of Bausch Health US, LLC
Payment Record ID 589415949
10/29/2018 General (Non-Research) In-kind items and services Food and Beverage $17.02 Details
Payment from Salix Pharmaceuticals, a division of Bausch Health US, LLC
Payment Record ID 589415944
10/29/2018 General (Non-Research) In-kind items and services Food and Beverage $18.06 Details
Payment from Salix Pharmaceuticals, a division of Bausch Health US, LLC
Payment Record ID 589415941
10/08/2018 General (Non-Research) In-kind items and services Food and Beverage $15.76 Details
Payment from Salix Pharmaceuticals, a division of Bausch Health US, LLC
Payment Record ID 589415937
07/27/2018 General (Non-Research) In-kind items and services Food and Beverage $12.83 Details
Payment from Salix Pharmaceuticals, a division of Bausch Health US, LLC
Payment Record ID 589415933
07/16/2018 General (Non-Research) In-kind items and services Food and Beverage $16.69 Details
Payment from Salix Pharmaceuticals, a division of Bausch Health US, LLC
Payment Record ID 589415929
07/02/2018 General (Non-Research) In-kind items and services Food and Beverage $10.91 Details
Payment from Salix Pharmaceuticals, a division of Bausch Health US, LLC
Payment Record ID 589415925
07/02/2018 General (Non-Research) In-kind items and services Food and Beverage $6.12 Details
Payment from Salix Pharmaceuticals, a division of Bausch Health US, LLC
Payment Record ID 589415923
04/16/2018 General (Non-Research) In-kind items and services Food and Beverage $13.42 Details
Payment from Salix Pharmaceuticals, a division of Bausch Health US, LLC
Payment Record ID 589415919
04/16/2018 General (Non-Research) In-kind items and services Food and Beverage $19.56 Details
Payment from Salix Pharmaceuticals, a division of Bausch Health US, LLC
Payment Record ID 589415915
04/04/2018 General (Non-Research) In-kind items and services Food and Beverage $1.98 Details
Payment from Salix Pharmaceuticals, a division of Bausch Health US, LLC
Payment Record ID 589415909
04/04/2018 General (Non-Research) In-kind items and services Food and Beverage $7.97 Details
Payment from Salix Pharmaceuticals, a division of Bausch Health US, LLC
Payment Record ID 589415906
03/21/2018 General (Non-Research) In-kind items and services Food and Beverage $16.79 Details
Payment from Salix Pharmaceuticals, a division of Bausch Health US, LLC
Payment Record ID 589415901
03/05/2018 General (Non-Research) In-kind items and services Food and Beverage $3.46 Details
Payment from Salix Pharmaceuticals, a division of Bausch Health US, LLC
Payment Record ID 589415899
03/05/2018 General (Non-Research) In-kind items and services Food and Beverage $17.69 Details
Payment from Salix Pharmaceuticals, a division of Bausch Health US, LLC
Payment Record ID 589415894
01/23/2018 General (Non-Research) In-kind items and services Food and Beverage $15.43 Details
Payment from Salix Pharmaceuticals, a division of Bausch Health US, LLC
Payment Record ID 589415889
07/26/2018 Research In-kind items and services $723.94 Details
Payment from Eli Lilly and Company
Paymment Research Study A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL, PLACEBO-CONTROLLED INDUCTION STUDY OF MIRIKIZUMAB IN CONVENTIONAL-FAILED AND BIOLOGIC-FAILED PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (LUCENT 1)
Clinical Trials Gov ID NCT03518086
Payment Record ID 585603819
04/11/2018 Research Cash or cash equivalent Drug $1860.00 Details
Payment from Bausch Health US, LLC
Paymment Research Study A Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Multiregional, One Year Study to Assess the Efficacy and Safety of Twice Daily Oral Rifaximin Delayed Release Tablets for Induction of Clinical Remission With Endoscopic Response at 16 Weeks Followed by Clinical and Endoscopic Remission at 52 Weeks in Subjects With Active Moderate Crohn's Disease
Clinical Trials Gov ID NCT02240108
Payment Record ID 582830649
04/06/2018 Research Cash or cash equivalent Drug $185.00 Details
Payment from Bausch Health US, LLC
Paymment Research Study A Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Multiregional, One Year Study to Assess the Efficacy and Safety of Twice Daily Oral Rifaximin Delayed Release Tablets for Induction of Clinical Remission With Endoscopic Response at 16 Weeks Followed by Clinical and Endoscopic Remission at 52 Weeks in Subjects With Active Moderate Crohn's Disease
Clinical Trials Gov ID NCT02240108
Payment Record ID 582830647
03/31/2018 Research Cash or cash equivalent Drug $110.00 Details
Payment from Bausch Health US, LLC
Paymment Research Study A Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Multiregional, One Year Study to Assess the Efficacy and Safety of Twice Daily Oral Rifaximin Delayed Release Tablets for Induction of Clinical Remission With Endoscopic Response at 16 Weeks Followed by Clinical and Endoscopic Remission at 52 Weeks in Subjects With Active Moderate Crohn's Disease
Clinical Trials Gov ID NCT02240108
Payment Record ID 582830643
03/31/2018 Research Cash or cash equivalent Drug $110.00 Details
Payment from Bausch Health US, LLC
Paymment Research Study A Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Multiregional, One Year Study to Assess the Efficacy and Safety of Twice Daily Oral Rifaximin Delayed Release Tablets for Induction of Clinical Remission With Endoscopic Response at 16 Weeks Followed by Clinical and Endoscopic Remission at 52 Weeks in Subjects With Active Moderate Crohn's Disease
Clinical Trials Gov ID NCT02240108
Payment Record ID 582830639
03/31/2018 Research Cash or cash equivalent Drug $171.00 Details
Payment from Bausch Health US, LLC
Paymment Research Study A Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Multiregional, One Year Study to Assess the Efficacy and Safety of Twice Daily Oral Rifaximin Delayed Release Tablets for Induction of Clinical Remission With Endoscopic Response at 16 Weeks Followed by Clinical and Endoscopic Remission at 52 Weeks in Subjects With Active Moderate Crohn's Disease
Clinical Trials Gov ID NCT02240108
Payment Record ID 582830637
03/31/2018 Research Cash or cash equivalent Drug $83.00 Details
Payment from Bausch Health US, LLC
Paymment Research Study A Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Multiregional, One Year Study to Assess the Efficacy and Safety of Twice Daily Oral Rifaximin Delayed Release Tablets for Induction of Clinical Remission With Endoscopic Response at 16 Weeks Followed by Clinical and Endoscopic Remission at 52 Weeks in Subjects With Active Moderate Crohn's Disease
Clinical Trials Gov ID NCT02240108
Payment Record ID 582830633
03/31/2018 Research Cash or cash equivalent Drug $171.00 Details
Payment from Bausch Health US, LLC
Paymment Research Study A Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Multiregional, One Year Study to Assess the Efficacy and Safety of Twice Daily Oral Rifaximin Delayed Release Tablets for Induction of Clinical Remission With Endoscopic Response at 16 Weeks Followed by Clinical and Endoscopic Remission at 52 Weeks in Subjects With Active Moderate Crohn's Disease
Clinical Trials Gov ID NCT02240108
Payment Record ID 582830631
03/31/2018 Research Cash or cash equivalent Drug $83.00 Details
Payment from Bausch Health US, LLC
Paymment Research Study A Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Multiregional, One Year Study to Assess the Efficacy and Safety of Twice Daily Oral Rifaximin Delayed Release Tablets for Induction of Clinical Remission With Endoscopic Response at 16 Weeks Followed by Clinical and Endoscopic Remission at 52 Weeks in Subjects With Active Moderate Crohn's Disease
Clinical Trials Gov ID NCT02240108
Payment Record ID 582830627
03/31/2018 Research Cash or cash equivalent Drug $96.00 Details
Payment from Bausch Health US, LLC
Paymment Research Study A Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Multiregional, One Year Study to Assess the Efficacy and Safety of Twice Daily Oral Rifaximin Delayed Release Tablets for Induction of Clinical Remission With Endoscopic Response at 16 Weeks Followed by Clinical and Endoscopic Remission at 52 Weeks in Subjects With Active Moderate Crohn's Disease
Clinical Trials Gov ID NCT02240108
Payment Record ID 582830623
03/31/2018 Research Cash or cash equivalent Drug $171.00 Details
Payment from Bausch Health US, LLC
Paymment Research Study A Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Multiregional, One Year Study to Assess the Efficacy and Safety of Twice Daily Oral Rifaximin Delayed Release Tablets for Induction of Clinical Remission With Endoscopic Response at 16 Weeks Followed by Clinical and Endoscopic Remission at 52 Weeks in Subjects With Active Moderate Crohn's Disease
Clinical Trials Gov ID NCT02240108
Payment Record ID 582830619
03/31/2018 Research Cash or cash equivalent Drug $171.00 Details
Payment from Bausch Health US, LLC
Paymment Research Study A Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Multiregional, One Year Study to Assess the Efficacy and Safety of Twice Daily Oral Rifaximin Delayed Release Tablets for Induction of Clinical Remission With Endoscopic Response at 16 Weeks Followed by Clinical and Endoscopic Remission at 52 Weeks in Subjects With Active Moderate Crohn's Disease
Clinical Trials Gov ID NCT02240108
Payment Record ID 582830615
03/31/2018 Research Cash or cash equivalent Drug $171.00 Details
Payment from Bausch Health US, LLC
Paymment Research Study A Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Multiregional, One Year Study to Assess the Efficacy and Safety of Twice Daily Oral Rifaximin Delayed Release Tablets for Induction of Clinical Remission With Endoscopic Response at 16 Weeks Followed by Clinical and Endoscopic Remission at 52 Weeks in Subjects With Active Moderate Crohn's Disease
Clinical Trials Gov ID NCT02240108
Payment Record ID 582830610
03/31/2018 Research Cash or cash equivalent Drug $140.00 Details
Payment from Bausch Health US, LLC
Paymment Research Study A Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Multiregional, One Year Study to Assess the Efficacy and Safety of Twice Daily Oral Rifaximin Delayed Release Tablets for Induction of Clinical Remission With Endoscopic Response at 16 Weeks Followed by Clinical and Endoscopic Remission at 52 Weeks in Subjects With Active Moderate Crohn's Disease
Clinical Trials Gov ID NCT02240108
Payment Record ID 582830607
03/31/2018 Research Cash or cash equivalent Drug $88.00 Details
Payment from Bausch Health US, LLC
Paymment Research Study A Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Multiregional, One Year Study to Assess the Efficacy and Safety of Twice Daily Oral Rifaximin Delayed Release Tablets for Induction of Clinical Remission With Endoscopic Response at 16 Weeks Followed by Clinical and Endoscopic Remission at 52 Weeks in Subjects With Active Moderate Crohn's Disease
Clinical Trials Gov ID NCT02240108
Payment Record ID 582830605
03/31/2018 Research Cash or cash equivalent Drug $185.00 Details
Payment from Bausch Health US, LLC
Paymment Research Study A Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Multiregional, One Year Study to Assess the Efficacy and Safety of Twice Daily Oral Rifaximin Delayed Release Tablets for Induction of Clinical Remission With Endoscopic Response at 16 Weeks Followed by Clinical and Endoscopic Remission at 52 Weeks in Subjects With Active Moderate Crohn's Disease
Clinical Trials Gov ID NCT02240108
Payment Record ID 582830599
03/31/2018 Research Cash or cash equivalent Drug $83.00 Details
Payment from Bausch Health US, LLC
Paymment Research Study A Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Multiregional, One Year Study to Assess the Efficacy and Safety of Twice Daily Oral Rifaximin Delayed Release Tablets for Induction of Clinical Remission With Endoscopic Response at 16 Weeks Followed by Clinical and Endoscopic Remission at 52 Weeks in Subjects With Active Moderate Crohn's Disease
Clinical Trials Gov ID NCT02240108
Payment Record ID 582830595
03/31/2018 Research Cash or cash equivalent Drug $88.00 Details
Payment from Bausch Health US, LLC
Paymment Research Study A Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Multiregional, One Year Study to Assess the Efficacy and Safety of Twice Daily Oral Rifaximin Delayed Release Tablets for Induction of Clinical Remission With Endoscopic Response at 16 Weeks Followed by Clinical and Endoscopic Remission at 52 Weeks in Subjects With Active Moderate Crohn's Disease
Clinical Trials Gov ID NCT02240108
Payment Record ID 582830592
03/31/2018 Research Cash or cash equivalent Drug $171.00 Details
Payment from Bausch Health US, LLC
Paymment Research Study A Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Multiregional, One Year Study to Assess the Efficacy and Safety of Twice Daily Oral Rifaximin Delayed Release Tablets for Induction of Clinical Remission With Endoscopic Response at 16 Weeks Followed by Clinical and Endoscopic Remission at 52 Weeks in Subjects With Active Moderate Crohn's Disease
Clinical Trials Gov ID NCT02240108
Payment Record ID 582830589
03/31/2018 Research Cash or cash equivalent Drug $79.00 Details
Payment from Bausch Health US, LLC
Paymment Research Study A Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Multiregional, One Year Study to Assess the Efficacy and Safety of Twice Daily Oral Rifaximin Delayed Release Tablets for Induction of Clinical Remission With Endoscopic Response at 16 Weeks Followed by Clinical and Endoscopic Remission at 52 Weeks in Subjects With Active Moderate Crohn's Disease
Clinical Trials Gov ID NCT02240108
Payment Record ID 582830585
03/31/2018 Research Cash or cash equivalent Drug $140.00 Details
Payment from Bausch Health US, LLC
Paymment Research Study A Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Multiregional, One Year Study to Assess the Efficacy and Safety of Twice Daily Oral Rifaximin Delayed Release Tablets for Induction of Clinical Remission With Endoscopic Response at 16 Weeks Followed by Clinical and Endoscopic Remission at 52 Weeks in Subjects With Active Moderate Crohn's Disease
Clinical Trials Gov ID NCT02240108
Payment Record ID 582830583
03/31/2018 Research Cash or cash equivalent Drug $83.00 Details
Payment from Bausch Health US, LLC
Paymment Research Study A Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Multiregional, One Year Study to Assess the Efficacy and Safety of Twice Daily Oral Rifaximin Delayed Release Tablets for Induction of Clinical Remission With Endoscopic Response at 16 Weeks Followed by Clinical and Endoscopic Remission at 52 Weeks in Subjects With Active Moderate Crohn's Disease
Clinical Trials Gov ID NCT02240108
Payment Record ID 582830579
03/31/2018 Research Cash or cash equivalent Drug $99.00 Details
Payment from Bausch Health US, LLC
Paymment Research Study A Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Multiregional, One Year Study to Assess the Efficacy and Safety of Twice Daily Oral Rifaximin Delayed Release Tablets for Induction of Clinical Remission With Endoscopic Response at 16 Weeks Followed by Clinical and Endoscopic Remission at 52 Weeks in Subjects With Active Moderate Crohn's Disease
Clinical Trials Gov ID NCT02240108
Payment Record ID 582830577
03/31/2018 Research Cash or cash equivalent Drug $35.00 Details
Payment from Bausch Health US, LLC
Paymment Research Study A Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Multiregional, One Year Study to Assess the Efficacy and Safety of Twice Daily Oral Rifaximin Delayed Release Tablets for Induction of Clinical Remission With Endoscopic Response at 16 Weeks Followed by Clinical and Endoscopic Remission at 52 Weeks in Subjects With Active Moderate Crohn's Disease
Clinical Trials Gov ID NCT02240108
Payment Record ID 582830573
03/31/2018 Research Cash or cash equivalent Drug $140.00 Details
Payment from Bausch Health US, LLC
Paymment Research Study A Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Multiregional, One Year Study to Assess the Efficacy and Safety of Twice Daily Oral Rifaximin Delayed Release Tablets for Induction of Clinical Remission With Endoscopic Response at 16 Weeks Followed by Clinical and Endoscopic Remission at 52 Weeks in Subjects With Active Moderate Crohn's Disease
Clinical Trials Gov ID NCT02240108
Payment Record ID 582830571
03/31/2018 Research Cash or cash equivalent Drug $171.00 Details
Payment from Bausch Health US, LLC
Paymment Research Study A Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Multiregional, One Year Study to Assess the Efficacy and Safety of Twice Daily Oral Rifaximin Delayed Release Tablets for Induction of Clinical Remission With Endoscopic Response at 16 Weeks Followed by Clinical and Endoscopic Remission at 52 Weeks in Subjects With Active Moderate Crohn's Disease
Clinical Trials Gov ID NCT02240108
Payment Record ID 582830567
03/31/2018 Research Cash or cash equivalent Drug $83.00 Details
Payment from Bausch Health US, LLC
Paymment Research Study A Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Multiregional, One Year Study to Assess the Efficacy and Safety of Twice Daily Oral Rifaximin Delayed Release Tablets for Induction of Clinical Remission With Endoscopic Response at 16 Weeks Followed by Clinical and Endoscopic Remission at 52 Weeks in Subjects With Active Moderate Crohn's Disease
Clinical Trials Gov ID NCT02240108
Payment Record ID 582830565
03/31/2018 Research Cash or cash equivalent Drug $173.00 Details
Payment from Bausch Health US, LLC
Paymment Research Study A Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Multiregional, One Year Study to Assess the Efficacy and Safety of Twice Daily Oral Rifaximin Delayed Release Tablets for Induction of Clinical Remission With Endoscopic Response at 16 Weeks Followed by Clinical and Endoscopic Remission at 52 Weeks in Subjects With Active Moderate Crohn's Disease
Clinical Trials Gov ID NCT02240108
Payment Record ID 582830563
03/31/2018 Research Cash or cash equivalent Drug $110.00 Details
Payment from Bausch Health US, LLC
Paymment Research Study A Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Multiregional, One Year Study to Assess the Efficacy and Safety of Twice Daily Oral Rifaximin Delayed Release Tablets for Induction of Clinical Remission With Endoscopic Response at 16 Weeks Followed by Clinical and Endoscopic Remission at 52 Weeks in Subjects With Active Moderate Crohn's Disease
Clinical Trials Gov ID NCT02240108
Payment Record ID 582830559
03/31/2018 Research Cash or cash equivalent Drug $140.00 Details
Payment from Bausch Health US, LLC
Paymment Research Study A Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Multiregional, One Year Study to Assess the Efficacy and Safety of Twice Daily Oral Rifaximin Delayed Release Tablets for Induction of Clinical Remission With Endoscopic Response at 16 Weeks Followed by Clinical and Endoscopic Remission at 52 Weeks in Subjects With Active Moderate Crohn's Disease
Clinical Trials Gov ID NCT02240108
Payment Record ID 582830555
03/31/2018 Research Cash or cash equivalent Drug $79.00 Details
Payment from Bausch Health US, LLC
Paymment Research Study A Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Multiregional, One Year Study to Assess the Efficacy and Safety of Twice Daily Oral Rifaximin Delayed Release Tablets for Induction of Clinical Remission With Endoscopic Response at 16 Weeks Followed by Clinical and Endoscopic Remission at 52 Weeks in Subjects With Active Moderate Crohn's Disease
Clinical Trials Gov ID NCT02240108
Payment Record ID 582830551
03/31/2018 Research Cash or cash equivalent Drug $35.00 Details
Payment from Bausch Health US, LLC
Paymment Research Study A Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Multiregional, One Year Study to Assess the Efficacy and Safety of Twice Daily Oral Rifaximin Delayed Release Tablets for Induction of Clinical Remission With Endoscopic Response at 16 Weeks Followed by Clinical and Endoscopic Remission at 52 Weeks in Subjects With Active Moderate Crohn's Disease
Clinical Trials Gov ID NCT02240108
Payment Record ID 582830547
03/31/2018 Research Cash or cash equivalent Drug $99.00 Details
Payment from Bausch Health US, LLC
Paymment Research Study A Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Multiregional, One Year Study to Assess the Efficacy and Safety of Twice Daily Oral Rifaximin Delayed Release Tablets for Induction of Clinical Remission With Endoscopic Response at 16 Weeks Followed by Clinical and Endoscopic Remission at 52 Weeks in Subjects With Active Moderate Crohn's Disease
Clinical Trials Gov ID NCT02240108
Payment Record ID 582830545
03/31/2018 Research Cash or cash equivalent Drug $88.00 Details
Payment from Bausch Health US, LLC
Paymment Research Study A Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Multiregional, One Year Study to Assess the Efficacy and Safety of Twice Daily Oral Rifaximin Delayed Release Tablets for Induction of Clinical Remission With Endoscopic Response at 16 Weeks Followed by Clinical and Endoscopic Remission at 52 Weeks in Subjects With Active Moderate Crohn's Disease
Clinical Trials Gov ID NCT02240108
Payment Record ID 582830541
03/31/2018 Research Cash or cash equivalent Drug $171.00 Details
Payment from Bausch Health US, LLC
Paymment Research Study A Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Multiregional, One Year Study to Assess the Efficacy and Safety of Twice Daily Oral Rifaximin Delayed Release Tablets for Induction of Clinical Remission With Endoscopic Response at 16 Weeks Followed by Clinical and Endoscopic Remission at 52 Weeks in Subjects With Active Moderate Crohn's Disease
Clinical Trials Gov ID NCT02240108
Payment Record ID 582830539
03/31/2018 Research Cash or cash equivalent Drug $110.00 Details
Payment from Bausch Health US, LLC
Paymment Research Study A Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Multiregional, One Year Study to Assess the Efficacy and Safety of Twice Daily Oral Rifaximin Delayed Release Tablets for Induction of Clinical Remission With Endoscopic Response at 16 Weeks Followed by Clinical and Endoscopic Remission at 52 Weeks in Subjects With Active Moderate Crohn's Disease
Clinical Trials Gov ID NCT02240108
Payment Record ID 582830535
03/31/2018 Research Cash or cash equivalent Drug $110.00 Details
Payment from Bausch Health US, LLC
Paymment Research Study A Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Multiregional, One Year Study to Assess the Efficacy and Safety of Twice Daily Oral Rifaximin Delayed Release Tablets for Induction of Clinical Remission With Endoscopic Response at 16 Weeks Followed by Clinical and Endoscopic Remission at 52 Weeks in Subjects With Active Moderate Crohn's Disease
Clinical Trials Gov ID NCT02240108
Payment Record ID 582830533
03/31/2018 Research Cash or cash equivalent Drug $140.00 Details
Payment from Bausch Health US, LLC
Paymment Research Study A Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Multiregional, One Year Study to Assess the Efficacy and Safety of Twice Daily Oral Rifaximin Delayed Release Tablets for Induction of Clinical Remission With Endoscopic Response at 16 Weeks Followed by Clinical and Endoscopic Remission at 52 Weeks in Subjects With Active Moderate Crohn's Disease
Clinical Trials Gov ID NCT02240108
Payment Record ID 582830531
03/31/2018 Research Cash or cash equivalent Drug $83.00 Details
Payment from Bausch Health US, LLC
Paymment Research Study A Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Multiregional, One Year Study to Assess the Efficacy and Safety of Twice Daily Oral Rifaximin Delayed Release Tablets for Induction of Clinical Remission With Endoscopic Response at 16 Weeks Followed by Clinical and Endoscopic Remission at 52 Weeks in Subjects With Active Moderate Crohn's Disease
Clinical Trials Gov ID NCT02240108
Payment Record ID 582830527
03/31/2018 Research Cash or cash equivalent Drug $140.00 Details
Payment from Bausch Health US, LLC
Paymment Research Study A Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Multiregional, One Year Study to Assess the Efficacy and Safety of Twice Daily Oral Rifaximin Delayed Release Tablets for Induction of Clinical Remission With Endoscopic Response at 16 Weeks Followed by Clinical and Endoscopic Remission at 52 Weeks in Subjects With Active Moderate Crohn's Disease
Clinical Trials Gov ID NCT02240108
Payment Record ID 582830523
03/31/2018 Research Cash or cash equivalent Drug $173.00 Details
Payment from Bausch Health US, LLC
Paymment Research Study A Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Multiregional, One Year Study to Assess the Efficacy and Safety of Twice Daily Oral Rifaximin Delayed Release Tablets for Induction of Clinical Remission With Endoscopic Response at 16 Weeks Followed by Clinical and Endoscopic Remission at 52 Weeks in Subjects With Active Moderate Crohn's Disease
Clinical Trials Gov ID NCT02240108
Payment Record ID 582830517
03/31/2018 Research Cash or cash equivalent Drug $171.00 Details
Payment from Bausch Health US, LLC
Paymment Research Study A Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Multiregional, One Year Study to Assess the Efficacy and Safety of Twice Daily Oral Rifaximin Delayed Release Tablets for Induction of Clinical Remission With Endoscopic Response at 16 Weeks Followed by Clinical and Endoscopic Remission at 52 Weeks in Subjects With Active Moderate Crohn's Disease
Clinical Trials Gov ID NCT02240108
Payment Record ID 582830515
03/31/2018 Research Cash or cash equivalent Drug $83.00 Details
Payment from Bausch Health US, LLC
Paymment Research Study A Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Multiregional, One Year Study to Assess the Efficacy and Safety of Twice Daily Oral Rifaximin Delayed Release Tablets for Induction of Clinical Remission With Endoscopic Response at 16 Weeks Followed by Clinical and Endoscopic Remission at 52 Weeks in Subjects With Active Moderate Crohn's Disease
Clinical Trials Gov ID NCT02240108
Payment Record ID 582830511
03/31/2018 Research Cash or cash equivalent Drug $171.00 Details
Payment from Bausch Health US, LLC
Paymment Research Study A Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Multiregional, One Year Study to Assess the Efficacy and Safety of Twice Daily Oral Rifaximin Delayed Release Tablets for Induction of Clinical Remission With Endoscopic Response at 16 Weeks Followed by Clinical and Endoscopic Remission at 52 Weeks in Subjects With Active Moderate Crohn's Disease
Clinical Trials Gov ID NCT02240108
Payment Record ID 582830509
03/31/2018 Research Cash or cash equivalent Drug $140.00 Details
Payment from Bausch Health US, LLC
Paymment Research Study A Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Multiregional, One Year Study to Assess the Efficacy and Safety of Twice Daily Oral Rifaximin Delayed Release Tablets for Induction of Clinical Remission With Endoscopic Response at 16 Weeks Followed by Clinical and Endoscopic Remission at 52 Weeks in Subjects With Active Moderate Crohn's Disease
Clinical Trials Gov ID NCT02240108
Payment Record ID 582830507
03/31/2018 Research Cash or cash equivalent Drug $79.00 Details
Payment from Bausch Health US, LLC
Paymment Research Study A Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Multiregional, One Year Study to Assess the Efficacy and Safety of Twice Daily Oral Rifaximin Delayed Release Tablets for Induction of Clinical Remission With Endoscopic Response at 16 Weeks Followed by Clinical and Endoscopic Remission at 52 Weeks in Subjects With Active Moderate Crohn's Disease
Clinical Trials Gov ID NCT02240108
Payment Record ID 582830503
03/31/2018 Research Cash or cash equivalent Drug $140.00 Details
Payment from Bausch Health US, LLC
Paymment Research Study A Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Multiregional, One Year Study to Assess the Efficacy and Safety of Twice Daily Oral Rifaximin Delayed Release Tablets for Induction of Clinical Remission With Endoscopic Response at 16 Weeks Followed by Clinical and Endoscopic Remission at 52 Weeks in Subjects With Active Moderate Crohn's Disease
Clinical Trials Gov ID NCT02240108
Payment Record ID 582830501
03/31/2018 Research Cash or cash equivalent Drug $169.00 Details
Payment from Bausch Health US, LLC
Paymment Research Study A Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Multiregional, One Year Study to Assess the Efficacy and Safety of Twice Daily Oral Rifaximin Delayed Release Tablets for Induction of Clinical Remission With Endoscopic Response at 16 Weeks Followed by Clinical and Endoscopic Remission at 52 Weeks in Subjects With Active Moderate Crohn's Disease
Clinical Trials Gov ID NCT02240108
Payment Record ID 582830497
03/31/2018 Research Cash or cash equivalent Drug $83.00 Details
Payment from Bausch Health US, LLC
Paymment Research Study A Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Multiregional, One Year Study to Assess the Efficacy and Safety of Twice Daily Oral Rifaximin Delayed Release Tablets for Induction of Clinical Remission With Endoscopic Response at 16 Weeks Followed by Clinical and Endoscopic Remission at 52 Weeks in Subjects With Active Moderate Crohn's Disease
Clinical Trials Gov ID NCT02240108
Payment Record ID 582830495
03/31/2018 Research Cash or cash equivalent Drug $83.00 Details
Payment from Bausch Health US, LLC
Paymment Research Study A Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Multiregional, One Year Study to Assess the Efficacy and Safety of Twice Daily Oral Rifaximin Delayed Release Tablets for Induction of Clinical Remission With Endoscopic Response at 16 Weeks Followed by Clinical and Endoscopic Remission at 52 Weeks in Subjects With Active Moderate Crohn's Disease
Clinical Trials Gov ID NCT02240108
Payment Record ID 582830493
03/31/2018 Research Cash or cash equivalent Drug $105.00 Details
Payment from Bausch Health US, LLC
Paymment Research Study A Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Multiregional, One Year Study to Assess the Efficacy and Safety of Twice Daily Oral Rifaximin Delayed Release Tablets for Induction of Clinical Remission With Endoscopic Response at 16 Weeks Followed by Clinical and Endoscopic Remission at 52 Weeks in Subjects With Active Moderate Crohn's Disease
Clinical Trials Gov ID NCT02240108
Payment Record ID 582830489
03/31/2018 Research Cash or cash equivalent Drug $35.00 Details
Payment from Bausch Health US, LLC
Paymment Research Study A Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Multiregional, One Year Study to Assess the Efficacy and Safety of Twice Daily Oral Rifaximin Delayed Release Tablets for Induction of Clinical Remission With Endoscopic Response at 16 Weeks Followed by Clinical and Endoscopic Remission at 52 Weeks in Subjects With Active Moderate Crohn's Disease
Clinical Trials Gov ID NCT02240108
Payment Record ID 582830485
03/31/2018 Research Cash or cash equivalent Drug $83.00 Details
Payment from Bausch Health US, LLC
Paymment Research Study A Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Multiregional, One Year Study to Assess the Efficacy and Safety of Twice Daily Oral Rifaximin Delayed Release Tablets for Induction of Clinical Remission With Endoscopic Response at 16 Weeks Followed by Clinical and Endoscopic Remission at 52 Weeks in Subjects With Active Moderate Crohn's Disease
Clinical Trials Gov ID NCT02240108
Payment Record ID 582830481
03/31/2018 Research Cash or cash equivalent Drug $99.00 Details
Payment from Bausch Health US, LLC
Paymment Research Study A Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Multiregional, One Year Study to Assess the Efficacy and Safety of Twice Daily Oral Rifaximin Delayed Release Tablets for Induction of Clinical Remission With Endoscopic Response at 16 Weeks Followed by Clinical and Endoscopic Remission at 52 Weeks in Subjects With Active Moderate Crohn's Disease
Clinical Trials Gov ID NCT02240108
Payment Record ID 582830478
03/31/2018 Research Cash or cash equivalent Drug $83.00 Details
Payment from Bausch Health US, LLC
Paymment Research Study A Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Multiregional, One Year Study to Assess the Efficacy and Safety of Twice Daily Oral Rifaximin Delayed Release Tablets for Induction of Clinical Remission With Endoscopic Response at 16 Weeks Followed by Clinical and Endoscopic Remission at 52 Weeks in Subjects With Active Moderate Crohn's Disease
Clinical Trials Gov ID NCT02240108
Payment Record ID 582830473
03/31/2018 Research Cash or cash equivalent Drug $105.00 Details
Payment from Bausch Health US, LLC
Paymment Research Study A Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Multiregional, One Year Study to Assess the Efficacy and Safety of Twice Daily Oral Rifaximin Delayed Release Tablets for Induction of Clinical Remission With Endoscopic Response at 16 Weeks Followed by Clinical and Endoscopic Remission at 52 Weeks in Subjects With Active Moderate Crohn's Disease
Clinical Trials Gov ID NCT02240108
Payment Record ID 582830469
03/31/2018 Research Cash or cash equivalent Drug $171.00 Details
Payment from Bausch Health US, LLC
Paymment Research Study A Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Multiregional, One Year Study to Assess the Efficacy and Safety of Twice Daily Oral Rifaximin Delayed Release Tablets for Induction of Clinical Remission With Endoscopic Response at 16 Weeks Followed by Clinical and Endoscopic Remission at 52 Weeks in Subjects With Active Moderate Crohn's Disease
Clinical Trials Gov ID NCT02240108
Payment Record ID 582830467
03/31/2018 Research Cash or cash equivalent Drug $171.00 Details
Payment from Bausch Health US, LLC
Paymment Research Study A Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Multiregional, One Year Study to Assess the Efficacy and Safety of Twice Daily Oral Rifaximin Delayed Release Tablets for Induction of Clinical Remission With Endoscopic Response at 16 Weeks Followed by Clinical and Endoscopic Remission at 52 Weeks in Subjects With Active Moderate Crohn's Disease
Clinical Trials Gov ID NCT02240108
Payment Record ID 582830463
03/31/2018 Research Cash or cash equivalent Drug $171.00 Details
Payment from Bausch Health US, LLC
Paymment Research Study A Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Multiregional, One Year Study to Assess the Efficacy and Safety of Twice Daily Oral Rifaximin Delayed Release Tablets for Induction of Clinical Remission With Endoscopic Response at 16 Weeks Followed by Clinical and Endoscopic Remission at 52 Weeks in Subjects With Active Moderate Crohn's Disease
Clinical Trials Gov ID NCT02240108
Payment Record ID 582830457
03/31/2018 Research Cash or cash equivalent Drug $83.00 Details
Payment from Bausch Health US, LLC
Paymment Research Study A Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Multiregional, One Year Study to Assess the Efficacy and Safety of Twice Daily Oral Rifaximin Delayed Release Tablets for Induction of Clinical Remission With Endoscopic Response at 16 Weeks Followed by Clinical and Endoscopic Remission at 52 Weeks in Subjects With Active Moderate Crohn's Disease
Clinical Trials Gov ID NCT02240108
Payment Record ID 582830453
03/31/2018 Research Cash or cash equivalent Drug $169.00 Details
Payment from Bausch Health US, LLC
Paymment Research Study A Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Multiregional, One Year Study to Assess the Efficacy and Safety of Twice Daily Oral Rifaximin Delayed Release Tablets for Induction of Clinical Remission With Endoscopic Response at 16 Weeks Followed by Clinical and Endoscopic Remission at 52 Weeks in Subjects With Active Moderate Crohn's Disease
Clinical Trials Gov ID NCT02240108
Payment Record ID 582830449
03/31/2018 Research Cash or cash equivalent Drug $110.00 Details
Payment from Bausch Health US, LLC
Paymment Research Study A Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Multiregional, One Year Study to Assess the Efficacy and Safety of Twice Daily Oral Rifaximin Delayed Release Tablets for Induction of Clinical Remission With Endoscopic Response at 16 Weeks Followed by Clinical and Endoscopic Remission at 52 Weeks in Subjects With Active Moderate Crohn's Disease
Clinical Trials Gov ID NCT02240108
Payment Record ID 582830447
03/31/2018 Research Cash or cash equivalent Drug $110.00 Details
Payment from Bausch Health US, LLC
Paymment Research Study A Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Multiregional, One Year Study to Assess the Efficacy and Safety of Twice Daily Oral Rifaximin Delayed Release Tablets for Induction of Clinical Remission With Endoscopic Response at 16 Weeks Followed by Clinical and Endoscopic Remission at 52 Weeks in Subjects With Active Moderate Crohn's Disease
Clinical Trials Gov ID NCT02240108
Payment Record ID 582830445
03/31/2018 Research Cash or cash equivalent Drug $171.00 Details
Payment from Bausch Health US, LLC
Paymment Research Study A Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Multiregional, One Year Study to Assess the Efficacy and Safety of Twice Daily Oral Rifaximin Delayed Release Tablets for Induction of Clinical Remission With Endoscopic Response at 16 Weeks Followed by Clinical and Endoscopic Remission at 52 Weeks in Subjects With Active Moderate Crohn's Disease
Clinical Trials Gov ID NCT02240108
Payment Record ID 582830439
03/31/2018 Research Cash or cash equivalent Drug $83.00 Details
Payment from Bausch Health US, LLC
Paymment Research Study A Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Multiregional, One Year Study to Assess the Efficacy and Safety of Twice Daily Oral Rifaximin Delayed Release Tablets for Induction of Clinical Remission With Endoscopic Response at 16 Weeks Followed by Clinical and Endoscopic Remission at 52 Weeks in Subjects With Active Moderate Crohn's Disease
Clinical Trials Gov ID NCT02240108
Payment Record ID 582830437
03/31/2018 Research Cash or cash equivalent Drug $171.00 Details
Payment from Bausch Health US, LLC
Paymment Research Study A Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Multiregional, One Year Study to Assess the Efficacy and Safety of Twice Daily Oral Rifaximin Delayed Release Tablets for Induction of Clinical Remission With Endoscopic Response at 16 Weeks Followed by Clinical and Endoscopic Remission at 52 Weeks in Subjects With Active Moderate Crohn's Disease
Clinical Trials Gov ID NCT02240108
Payment Record ID 582830435
03/31/2018 Research Cash or cash equivalent Drug $171.00 Details
Payment from Bausch Health US, LLC
Paymment Research Study A Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Multiregional, One Year Study to Assess the Efficacy and Safety of Twice Daily Oral Rifaximin Delayed Release Tablets for Induction of Clinical Remission With Endoscopic Response at 16 Weeks Followed by Clinical and Endoscopic Remission at 52 Weeks in Subjects With Active Moderate Crohn's Disease
Clinical Trials Gov ID NCT02240108
Payment Record ID 582830431
03/31/2018 Research Cash or cash equivalent Drug $140.00 Details
Payment from Bausch Health US, LLC
Paymment Research Study A Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Multiregional, One Year Study to Assess the Efficacy and Safety of Twice Daily Oral Rifaximin Delayed Release Tablets for Induction of Clinical Remission With Endoscopic Response at 16 Weeks Followed by Clinical and Endoscopic Remission at 52 Weeks in Subjects With Active Moderate Crohn's Disease
Clinical Trials Gov ID NCT02240108
Payment Record ID 582830429
03/31/2018 Research Cash or cash equivalent Drug $110.00 Details
Payment from Bausch Health US, LLC
Paymment Research Study A Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Multiregional, One Year Study to Assess the Efficacy and Safety of Twice Daily Oral Rifaximin Delayed Release Tablets for Induction of Clinical Remission With Endoscopic Response at 16 Weeks Followed by Clinical and Endoscopic Remission at 52 Weeks in Subjects With Active Moderate Crohn's Disease
Clinical Trials Gov ID NCT02240108
Payment Record ID 582830426
03/31/2018 Research Cash or cash equivalent Drug $171.00 Details
Payment from Bausch Health US, LLC
Paymment Research Study A Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Multiregional, One Year Study to Assess the Efficacy and Safety of Twice Daily Oral Rifaximin Delayed Release Tablets for Induction of Clinical Remission With Endoscopic Response at 16 Weeks Followed by Clinical and Endoscopic Remission at 52 Weeks in Subjects With Active Moderate Crohn's Disease
Clinical Trials Gov ID NCT02240108
Payment Record ID 582830423
03/31/2018 Research Cash or cash equivalent Drug $35.00 Details
Payment from Bausch Health US, LLC
Paymment Research Study A Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Multiregional, One Year Study to Assess the Efficacy and Safety of Twice Daily Oral Rifaximin Delayed Release Tablets for Induction of Clinical Remission With Endoscopic Response at 16 Weeks Followed by Clinical and Endoscopic Remission at 52 Weeks in Subjects With Active Moderate Crohn's Disease
Clinical Trials Gov ID NCT02240108
Payment Record ID 582830421
03/31/2018 Research Cash or cash equivalent Drug $105.00 Details
Payment from Bausch Health US, LLC
Paymment Research Study A Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Multiregional, One Year Study to Assess the Efficacy and Safety of Twice Daily Oral Rifaximin Delayed Release Tablets for Induction of Clinical Remission With Endoscopic Response at 16 Weeks Followed by Clinical and Endoscopic Remission at 52 Weeks in Subjects With Active Moderate Crohn's Disease
Clinical Trials Gov ID NCT02240108
Payment Record ID 582830419
03/31/2018 Research Cash or cash equivalent Drug $171.00 Details
Payment from Bausch Health US, LLC
Paymment Research Study A Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Multiregional, One Year Study to Assess the Efficacy and Safety of Twice Daily Oral Rifaximin Delayed Release Tablets for Induction of Clinical Remission With Endoscopic Response at 16 Weeks Followed by Clinical and Endoscopic Remission at 52 Weeks in Subjects With Active Moderate Crohn's Disease
Clinical Trials Gov ID NCT02240108
Payment Record ID 582830415
03/31/2018 Research Cash or cash equivalent Drug $171.00 Details
Payment from Bausch Health US, LLC
Paymment Research Study A Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Multiregional, One Year Study to Assess the Efficacy and Safety of Twice Daily Oral Rifaximin Delayed Release Tablets for Induction of Clinical Remission With Endoscopic Response at 16 Weeks Followed by Clinical and Endoscopic Remission at 52 Weeks in Subjects With Active Moderate Crohn's Disease
Clinical Trials Gov ID NCT02240108
Payment Record ID 582830411
03/31/2018 Research Cash or cash equivalent Drug $105.00 Details
Payment from Bausch Health US, LLC
Paymment Research Study A Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Multiregional, One Year Study to Assess the Efficacy and Safety of Twice Daily Oral Rifaximin Delayed Release Tablets for Induction of Clinical Remission With Endoscopic Response at 16 Weeks Followed by Clinical and Endoscopic Remission at 52 Weeks in Subjects With Active Moderate Crohn's Disease
Clinical Trials Gov ID NCT02240108
Payment Record ID 582830409
03/31/2018 Research Cash or cash equivalent Drug $140.00 Details
Payment from Bausch Health US, LLC
Paymment Research Study A Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Multiregional, One Year Study to Assess the Efficacy and Safety of Twice Daily Oral Rifaximin Delayed Release Tablets for Induction of Clinical Remission With Endoscopic Response at 16 Weeks Followed by Clinical and Endoscopic Remission at 52 Weeks in Subjects With Active Moderate Crohn's Disease
Clinical Trials Gov ID NCT02240108
Payment Record ID 582830406
01/25/2018 Research Cash or cash equivalent Drug $1279.00 Details
Payment from Bausch Health US, LLC
Paymment Research Study A Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Multiregional, One Year Study to Assess the Efficacy and Safety of Twice Daily Oral Rifaximin Delayed Release Tablets for Induction of Clinical Remission With Endoscopic Response at 16 Weeks Followed by Clinical and Endoscopic Remission at 52 Weeks in Subjects With Active Moderate Crohn's Disease
Clinical Trials Gov ID NCT02240108
Payment Record ID 582830403
01/11/2018 Research Cash or cash equivalent Drug $1163.00 Details
Payment from Bausch Health US, LLC
Paymment Research Study A Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Multiregional, One Year Study to Assess the Efficacy and Safety of Twice Daily Oral Rifaximin Delayed Release Tablets for Induction of Clinical Remission With Endoscopic Response at 16 Weeks Followed by Clinical and Endoscopic Remission at 52 Weeks in Subjects With Active Moderate Crohn's Disease
Clinical Trials Gov ID NCT02240108
Payment Record ID 582830399
01/11/2018 Research Cash or cash equivalent Drug $1104.00 Details
Payment from Bausch Health US, LLC
Paymment Research Study A Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Multiregional, One Year Study to Assess the Efficacy and Safety of Twice Daily Oral Rifaximin Delayed Release Tablets for Induction of Clinical Remission With Endoscopic Response at 16 Weeks Followed by Clinical and Endoscopic Remission at 52 Weeks in Subjects With Active Moderate Crohn's Disease
Clinical Trials Gov ID NCT02240108
Payment Record ID 582830397
01/11/2018 Research Cash or cash equivalent Drug $2244.00 Details
Payment from Bausch Health US, LLC
Paymment Research Study A Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Multiregional, One Year Study to Assess the Efficacy and Safety of Twice Daily Oral Rifaximin Delayed Release Tablets for Induction of Clinical Remission With Endoscopic Response at 16 Weeks Followed by Clinical and Endoscopic Remission at 52 Weeks in Subjects With Active Moderate Crohn's Disease
Clinical Trials Gov ID NCT02240108
Payment Record ID 582830393
01/11/2018 Research Cash or cash equivalent Drug $1395.00 Details
Payment from Bausch Health US, LLC
Paymment Research Study A Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Multiregional, One Year Study to Assess the Efficacy and Safety of Twice Daily Oral Rifaximin Delayed Release Tablets for Induction of Clinical Remission With Endoscopic Response at 16 Weeks Followed by Clinical and Endoscopic Remission at 52 Weeks in Subjects With Active Moderate Crohn's Disease
Clinical Trials Gov ID NCT02240108
Payment Record ID 582830387
08/06/2018 General (Non-Research) In-kind items and services Food and Beverage $14.09 Details
Payment from Prometheus Laboratories Inc.
Payment Record ID 576738519
08/06/2018 General (Non-Research) In-kind items and services Food and Beverage $11.78 Details
Payment from Prometheus Laboratories Inc.
Payment Record ID 576738515
07/24/2018 General (Non-Research) In-kind items and services Food and Beverage $22.14 Details
Payment from AbbVie, Inc.
Payment Record ID 571072695
06/07/2018 General (Non-Research) In-kind items and services Food and Beverage $67.68 Details
Payment from AbbVie, Inc.
Payment Record ID 570962343
03/29/2018 General (Non-Research) In-kind items and services Education $9.00 Details
Payment from AbbVie, Inc.
Payment Record ID 570809267
01/16/2018 General (Non-Research) In-kind items and services Food and Beverage $20.46 Details
Payment from AbbVie, Inc.
Payment Record ID 570556431
10/05/2018 General (Non-Research) In-kind items and services Food and Beverage $16.59 Details
Payment from Braintree Laboratories, Inc.
Payment Record ID 535586805
07/10/2018 General (Non-Research) In-kind items and services Food and Beverage $18.78 Details
Payment from Braintree Laboratories, Inc.
Payment Record ID 535586803
02/02/2018 General (Non-Research) In-kind items and services Food and Beverage $16.35 Details
Payment from Braintree Laboratories, Inc.
Payment Record ID 535586799
07/12/2017 General (Non-Research) In-kind items and services Food and Beverage $13.19 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 504181549
02/07/2017 General (Non-Research) In-kind items and services Food and Beverage $14.78 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 503290165
10/16/2017 General (Non-Research) In-kind items and services Food and Beverage $15.30 Details
Payment from Synergy Pharmaceuticals Inc
Payment Record ID 503272769
01/10/2017 General (Non-Research) In-kind items and services Food and Beverage $18.77 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 503158197
03/06/2017 General (Non-Research) In-kind items and services Food and Beverage $17.10 Details
Payment from Ironwood Pharmaceuticals, Inc
Payment Record ID 495718113
03/05/2017 General (Non-Research) In-kind items and services Food and Beverage $10.70 Details
Payment from Ironwood Pharmaceuticals, Inc
Payment Record ID 495685497
07/31/2017 General (Non-Research) In-kind items and services Food and Beverage $10.36 Details
Payment from Gilead Sciences Inc
Payment Record ID 480368169
05/30/2017 General (Non-Research) In-kind items and services Food and Beverage $11.16 Details
Payment from Gilead Sciences Inc
Payment Record ID 480368167
06/13/2017 Research Cash or cash equivalent Drug $4600.00 Details
Payment from Luitpold Pharmaceuticals Inc
Paymment Research Study IVIT13035
Clinical Trials Gov ID NCT02089668
Payment Record ID 478139873
03/27/2017 Research Cash or cash equivalent Drug $9450.00 Details
Payment from Luitpold Pharmaceuticals Inc
Paymment Research Study 1VIT13035
Clinical Trials Gov ID NCT02086968
Payment Record ID 478139731
09/15/2017 General (Non-Research) In-kind items and services Food and Beverage $317.84 Details
Payment from Allergan Inc.
Payment Record ID 470657121
06/17/2017 General (Non-Research) In-kind items and services Travel and Lodging $151.45 Details
Payment from Allergan Inc.
Payment Record ID 470657119
06/17/2017 General (Non-Research) In-kind items and services Travel and Lodging $269.70 Details
Payment from Allergan Inc.
Payment Record ID 470657115
06/15/2017 General (Non-Research) In-kind items and services Food and Beverage $3.67 Details
Payment from Allergan Inc.
Payment Record ID 470657111
06/15/2017 General (Non-Research) In-kind items and services Food and Beverage $13.81 Details
Payment from Allergan Inc.
Payment Record ID 470657107
06/17/2017 General (Non-Research) Cash or cash equivalent Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $1500.00 Details
Payment from Allergan Inc.
Payment Record ID 470657103
08/27/2017 General (Non-Research) In-kind items and services Food and Beverage $15.77 Details
Payment from Shire North American Group Inc
Payment Record ID 467228653
05/04/2017 General (Non-Research) In-kind items and services Food and Beverage $14.27 Details
Payment from Shire North American Group Inc
Payment Record ID 467228649
07/12/2017 Research Cash or cash equivalent $2900.00 Details
Payment from AbbVie, Inc.
Paymment Research Study M13-740
Clinical Trials Gov ID NCT02365649
Payment Record ID 462168467
01/24/2017 General (Non-Research) In-kind items and services Food and Beverage $16.48 Details
Payment from Janssen Biotech, Inc.
Payment Record ID 449827072
01/24/2017 General (Non-Research) In-kind items and services Food and Beverage $13.93 Details
Payment from Janssen Biotech, Inc.
Payment Record ID 449827070
08/28/2017 General (Non-Research) In-kind items and services Food and Beverage $4.28 Details
Payment from Valeant Pharmaceuticals North America LLC
Payment Record ID 444447957
08/28/2017 General (Non-Research) In-kind items and services Food and Beverage $17.50 Details
Payment from Valeant Pharmaceuticals North America LLC
Payment Record ID 444447955
08/28/2017 General (Non-Research) In-kind items and services Food and Beverage $23.63 Details
Payment from Valeant Pharmaceuticals North America LLC
Payment Record ID 444447953
06/26/2017 General (Non-Research) In-kind items and services Food and Beverage $22.39 Details
Payment from Valeant Pharmaceuticals North America LLC
Payment Record ID 444447951
06/05/2017 General (Non-Research) In-kind items and services Food and Beverage $29.84 Details
Payment from Valeant Pharmaceuticals North America LLC
Payment Record ID 444447949
02/07/2017 General (Non-Research) In-kind items and services Food and Beverage $4.16 Details
Payment from Valeant Pharmaceuticals North America LLC
Payment Record ID 444447947
02/07/2017 General (Non-Research) In-kind items and services Food and Beverage $20.80 Details
Payment from Valeant Pharmaceuticals North America LLC
Payment Record ID 444447945
10/29/2016 General (Non-Research) Cash or cash equivalent Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $1500.00 Details
Payment from Allergan Inc.
Payment Record ID 420616909
10/29/2016 General (Non-Research) In-kind items and services Food and Beverage $492.65 Details
Payment from Allergan Inc.
Payment Record ID 420615747
10/29/2016 General (Non-Research) In-kind items and services Travel and Lodging $397.08 Details
Payment from Allergan Inc.
Payment Record ID 420615183
10/29/2016 General (Non-Research) In-kind items and services Travel and Lodging $394.96 Details
Payment from Allergan Inc.
Payment Record ID 420615159
10/29/2016 General (Non-Research) In-kind items and services Food and Beverage $182.23 Details
Payment from Allergan Inc.
Payment Record ID 420613885
10/29/2016 General (Non-Research) In-kind items and services Travel and Lodging $29.00 Details
Payment from Allergan Inc.
Payment Record ID 420612193
10/29/2016 General (Non-Research) In-kind items and services Travel and Lodging $20.00 Details
Payment from Allergan Inc.
Payment Record ID 420611561
06/13/2016 General (Non-Research) In-kind items and services Food and Beverage $12.82 Details
Payment from Ironwood Pharmaceuticals, Inc
Payment Record ID 412377962
02/23/2016 General (Non-Research) In-kind items and services Food and Beverage $13.55 Details
Payment from Ironwood Pharmaceuticals, Inc
Payment Record ID 412377958
01/12/2016 General (Non-Research) In-kind items and services Food and Beverage $13.47 Details
Payment from Ironwood Pharmaceuticals, Inc
Payment Record ID 412377955
11/15/2016 General (Non-Research) In-kind items and services Food and Beverage $1.75 Details
Payment from Valeant Pharmaceuticals North America LLC
Payment Record ID 410383968
11/15/2016 General (Non-Research) In-kind items and services Food and Beverage $17.90 Details
Payment from Valeant Pharmaceuticals North America LLC
Payment Record ID 410383966
09/06/2016 General (Non-Research) In-kind items and services Food and Beverage $4.60 Details
Payment from Valeant Pharmaceuticals North America LLC
Payment Record ID 410383964
09/06/2016 General (Non-Research) In-kind items and services Food and Beverage $18.30 Details
Payment from Valeant Pharmaceuticals North America LLC
Payment Record ID 410383960
08/09/2016 General (Non-Research) In-kind items and services Food and Beverage $18.59 Details
Payment from Valeant Pharmaceuticals North America LLC
Payment Record ID 410383958
08/09/2016 General (Non-Research) In-kind items and services Food and Beverage $2.01 Details
Payment from Valeant Pharmaceuticals North America LLC
Payment Record ID 410383952
05/09/2016 General (Non-Research) In-kind items and services Food and Beverage $28.33 Details
Payment from Valeant Pharmaceuticals North America LLC
Payment Record ID 410383950
05/02/2016 General (Non-Research) In-kind items and services Food and Beverage $2.97 Details
Payment from Valeant Pharmaceuticals North America LLC
Payment Record ID 410383946
05/02/2016 General (Non-Research) In-kind items and services Food and Beverage $22.67 Details
Payment from Valeant Pharmaceuticals North America LLC
Payment Record ID 410383942
06/07/2016 General (Non-Research) In-kind items and services Food and Beverage $17.63 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 406456146
02/09/2016 General (Non-Research) In-kind items and services Food and Beverage $15.82 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 406373906
03/03/2016 General (Non-Research) In-kind items and services Food and Beverage $16.46 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 406311164
11/29/2016 General (Non-Research) In-kind items and services Food and Beverage $13.68 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 406104500
10/07/2016 General (Non-Research) Cash or cash equivalent Consulting Fee $200.00 Details
Payment from COMSORT, Inc
Payment Record ID 406097006
07/19/2016 General (Non-Research) In-kind items and services Food and Beverage $10.11 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 405988936
10/13/2016 General (Non-Research) In-kind items and services Food and Beverage $11.38 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 405926444
04/12/2016 General (Non-Research) In-kind items and services Food and Beverage $18.53 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 405864464
12/05/2016 General (Non-Research) In-kind items and services Food and Beverage $18.02 Details
Payment from AbbVie, Inc.
Payment Record ID 397226402
12/04/2016 General (Non-Research) In-kind items and services Food and Beverage $14.53 Details
Payment from AbbVie, Inc.
Payment Record ID 397189112
09/07/2016 General (Non-Research) Cash or cash equivalent Food and Beverage $12.39 Details
Payment from E.R. Squibb & Sons, L.L.C.
Payment Record ID 396992912
01/11/2016 General (Non-Research) In-kind items and services Food and Beverage $17.94 Details
Payment from AbbVie, Inc.
Payment Record ID 396520181
05/05/2016 General (Non-Research) In-kind items and services Food and Beverage $19.53 Details
Payment from AbbVie, Inc.
Payment Record ID 396444944
10/24/2016 Research Cash or cash equivalent $806.60 Details
Payment from AbbVie, Inc.
Paymment Research Study M13-740
Clinical Trials Gov ID NCT02365649
Payment Record ID 396408496
12/19/2016 Research Cash or cash equivalent $3257.50 Details
Payment from AbbVie, Inc.
Paymment Research Study M13-740
Clinical Trials Gov ID NCT02365649
Payment Record ID 396227222
09/07/2016 Research Cash or cash equivalent Biological $3000.00 Details
Payment from AbbVie, Inc.
Paymment Research Study M14-763
Payment Record ID 396159790
09/14/2016 Research Cash or cash equivalent $4064.10 Details
Payment from AbbVie, Inc.
Paymment Research Study M13-740
Clinical Trials Gov ID NCT02365649
Payment Record ID 396129591
08/22/2016 Research Cash or cash equivalent $1728.50 Details
Payment from AbbVie, Inc.
Paymment Research Study M13-740
Clinical Trials Gov ID NCT02365649
Payment Record ID 395993264
05/03/2016 General (Non-Research) In-kind items and services Food and Beverage $14.66 Details
Payment from AbbVie, Inc.
Payment Record ID 395748488
01/06/2016 Research Cash or cash equivalent $7427.00 Details
Payment from AbbVie, Inc.
Paymment Research Study M13-740
Clinical Trials Gov ID NCT02365649
Payment Record ID 395271668
03/23/2016 Research Cash or cash equivalent $148.40 Details
Payment from AbbVie, Inc.
Paymment Research Study M13-740
Clinical Trials Gov ID NCT02365649
Payment Record ID 395200957
03/02/2016 Research Cash or cash equivalent $1909.90 Details
Payment from AbbVie, Inc.
Paymment Research Study M13-740
Clinical Trials Gov ID NCT02365649
Payment Record ID 395200862
10/31/2016 General (Non-Research) In-kind items and services Food and Beverage $10.42 Details
Payment from Gilead Sciences Inc
Payment Record ID 392288260
07/11/2016 General (Non-Research) In-kind items and services Food and Beverage $13.15 Details
Payment from Gilead Sciences Inc
Payment Record ID 392288236
02/29/2016 General (Non-Research) In-kind items and services Food and Beverage $13.28 Details
Payment from Gilead Sciences Inc
Payment Record ID 392288202
09/06/2016 General (Non-Research) In-kind items and services Food and Beverage $13.76 Details
Payment from Takeda Pharmaceuticals America, Inc.
Payment Record ID 380089798
05/06/2016 General (Non-Research) In-kind items and services Food and Beverage $8.16 Details
Payment from Takeda Pharmaceuticals America, Inc.
Payment Record ID 380089792
02/09/2016 General (Non-Research) In-kind items and services Food and Beverage $9.69 Details
Payment from Takeda Pharmaceuticals America, Inc.
Payment Record ID 380089782
08/03/2016 General (Non-Research) Cash or cash equivalent Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $1400.00 Details
Payment from Allergan Inc.
Payment Record ID 379979851
02/22/2016 General (Non-Research) Cash or cash equivalent Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $1400.00 Details
Payment from Allergan Inc.
Payment Record ID 379979842
01/16/2016 General (Non-Research) In-kind items and services Food and Beverage $406.81 Details
Payment from Allergan Inc.
Payment Record ID 379979834
06/01/2016 General (Non-Research) Cash or cash equivalent Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $200.00 Details
Payment from Allergan Inc.
Payment Record ID 379979826
11/30/2016 General (Non-Research) In-kind items and services Food and Beverage $18.05 Details
Payment from Allergan Inc.
Payment Record ID 379979818
11/30/2016 General (Non-Research) In-kind items and services Food and Beverage $16.17 Details
Payment from Allergan Inc.
Payment Record ID 379979810
10/26/2016 General (Non-Research) In-kind items and services Food and Beverage $14.00 Details
Payment from Allergan Inc.
Payment Record ID 379979802
08/04/2016 General (Non-Research) In-kind items and services Food and Beverage $13.81 Details
Payment from Allergan Inc.
Payment Record ID 379979794
04/11/2016 General (Non-Research) In-kind items and services Food and Beverage $10.83 Details
Payment from Allergan Inc.
Payment Record ID 379979786
01/04/2016 General (Non-Research) In-kind items and services Food and Beverage $9.41 Details
Payment from Allergan Inc.
Payment Record ID 379979778
10/26/2016 General (Non-Research) In-kind items and services Food and Beverage $3.88 Details
Payment from Allergan Inc.
Payment Record ID 379979770
01/04/2016 General (Non-Research) In-kind items and services Food and Beverage $3.63 Details
Payment from Allergan Inc.
Payment Record ID 379979761
05/25/2016 General (Non-Research) In-kind items and services Food and Beverage $3.12 Details
Payment from Allergan Inc.
Payment Record ID 379979752
08/04/2016 General (Non-Research) In-kind items and services Food and Beverage $2.64 Details
Payment from Allergan Inc.
Payment Record ID 379979744
04/11/2016 General (Non-Research) In-kind items and services Food and Beverage $2.46 Details
Payment from Allergan Inc.
Payment Record ID 379979736
06/08/2016 General (Non-Research) In-kind items and services Food and Beverage $1.97 Details
Payment from Allergan Inc.
Payment Record ID 379979728
03/28/2016 General (Non-Research) In-kind items and services Food and Beverage $1.86 Details
Payment from Allergan Inc.
Payment Record ID 379979722
07/05/2016 General (Non-Research) In-kind items and services Food and Beverage $1.19 Details
Payment from Allergan Inc.
Payment Record ID 379979716
10/31/2016 General (Non-Research) In-kind items and services Food and Beverage $13.41 Details
Payment from Janssen Biotech, Inc.
Payment Record ID 365148140
11/28/2016 General (Non-Research) In-kind items and services Food and Beverage $12.71 Details
Payment from Janssen Biotech, Inc.
Payment Record ID 365148137
11/28/2016 General (Non-Research) In-kind items and services Food and Beverage $12.62 Details
Payment from Janssen Biotech, Inc.
Payment Record ID 365148134
10/31/2016 General (Non-Research) In-kind items and services Food and Beverage $13.51 Details
Payment from Janssen Biotech, Inc.
Payment Record ID 365148130
08/11/2016 General (Non-Research) In-kind items and services Food and Beverage $22.17 Details
Payment from Janssen Biotech, Inc.
Payment Record ID 365054466
08/11/2016 General (Non-Research) In-kind items and services Food and Beverage $13.51 Details
Payment from Janssen Biotech, Inc.
Payment Record ID 365054462
09/20/2016 General (Non-Research) In-kind items and services Food and Beverage $23.49 Details
Payment from Janssen Biotech, Inc.
Payment Record ID 365054458
09/20/2016 General (Non-Research) In-kind items and services Food and Beverage $14.39 Details
Payment from Janssen Biotech, Inc.
Payment Record ID 365054454
02/15/2016 General (Non-Research) In-kind items and services Food and Beverage $34.99 Details
Payment from Janssen Biotech, Inc.
Payment Record ID 364807874
02/15/2016 General (Non-Research) In-kind items and services Travel and Lodging $54.40 Details
Payment from Janssen Biotech, Inc.
Payment Record ID 364807348
02/15/2016 General (Non-Research) In-kind items and services Food and Beverage $27.41 Details
Payment from Janssen Biotech, Inc.
Payment Record ID 364805828
02/15/2016 General (Non-Research) In-kind items and services Food and Beverage $14.77 Details
Payment from Janssen Biotech, Inc.
Payment Record ID 364804810
02/15/2016 General (Non-Research) In-kind items and services Food and Beverage $150.21 Details
Payment from Janssen Biotech, Inc.
Payment Record ID 364803104
02/15/2016 General (Non-Research) In-kind items and services Travel and Lodging $720.10 Details
Payment from Janssen Biotech, Inc.
Payment Record ID 364800442
02/15/2016 General (Non-Research) Cash or cash equivalent Consulting Fee $2500.00 Details
Payment from Janssen Biotech, Inc.
Payment Record ID 364800268
;